RFK Jr.'s handpicked committee approves manufacture of peptides he uses

Published: Friday, July 24, 2026 at 7:10 pm

RFK Jr. Committee Votes to Ease Access to Unapproved Peptides

A handpicked advisory committee, established by Robert F. Kennedy Jr., has voted to overturn a ban on the manufacture of certain peptides, a move that raises significant concerns among health experts and regulators. The committee's decision, which saw newly appointed members voting in favor and pre-existing members voting against, paves the way for increased access to these substances despite a notable lack of safety and efficacy data.

Kennedy, who has expressed skepticism regarding the safety of established vaccine components, appears to be advocating for the use of peptides, which he and others are willing to inject without comprehensive safety information. While the Food and Drug Administration (FDA) has approved some peptide-based drugs, such as insulin and certain weight-loss medications, the majority have remained off the market due to insufficient data. The Biden administration had previously blocked their production by compounding pharmacies, which specialize in custom drug formulations.

However, Kennedy announced his intention to reverse this ban earlier this year. Critics, including Ars Beth Mole, had anticipated that Kennedy would appoint individuals with vested interests to the advisory board, potentially leading to a predetermined outcome favoring easier access to these drugs without rigorous scientific scrutiny. This prediction appears to have materialized, as a majority of the newly appointed members, with one exception, had clear ties to the manufacture and sale of unapproved peptides.

During the committee meeting, no scientific evidence was presented to support the safety or efficacy of the peptides in question. When questioned by a committee member about the FDA's practice of approving substances untested in humans, an FDA official stated that such approvals had not occurred. This assertion could prove crucial as the committee's role is advisory, leaving the final decision to the FDA. However, the FDA faces a potential conflict: rejecting the committee's recommendations could put its experts at odds with Kennedy, who possesses the authority to remove them.

BNN's Perspective: The decision by Robert F. Kennedy Jr.'s advisory committee to recommend easing restrictions on unapproved peptides, despite a lack of scientific evidence, is a concerning development. While patient access to treatments is important, it must be balanced with robust safety and efficacy standards. The potential for conflicts of interest within the committee, as suggested by critics, further amplifies these concerns. The FDA's ultimate decision will be critical in determining whether public health is prioritized over potentially premature access to untested substances.

Tags: RFK Jr., peptides, FDA, safety data, efficacy data, compounding pharmacies, ban, advisory committee, Biden administration, unapproved drugs

Full Story